Cancer Letters

, volume 214 , issue 1 , pages 115-120

Prostaglandin E2 activates Src signaling in lung adenocarcinoma cell via EP3

Tatsuya Yamaki ¹

Kiyoko Endoh ¹

Mituyoshi Miyahara ¹

Isao Nagamine ¹

Nguyen Thanh Huong ¹

Hidetoshi Sakurai ¹

Jan Pokorny ²

Tomohiro Yano ³

Hide authors affiliations Show authors affiliations: 3 affiliations

College of Bioresource Sciences, Nihon University, Fujisawa, Kanagawa, 252-8510, Japan. |

Faculty of Food and Biochemical Technology, Institute of Chemical Technology, CZ-16628 Prague 6, Czech Republic |

Department of Food Science Research for Health, National Institute of Health and Nutrition, 1-23-1 Toyama, Shinjuku-ku, Tokyo 162-8636, Japan |

Publication type: Journal Article

Publication date: 2004-10-01

Elsevier

Cancer Letters

scimago Q1

wos Q1

SJR: 2.756

CiteScore: 13.9

Impact factor: 10.1

ISSN: 03043835, 18727980

DOI: 10.1016/j.canlet.2004.04.013

Copy DOI

PubMed ID: 15331179

Cancer Research

Oncology

Abstract

Accumulating evidence suggests that overproduction of prostaglandin (PG) E2 attributable to induction of cyclooxygenase-2 plays an important role in the development of lung adenocarcinoma. Recently, we have reported that a PGE2 receptor, EP3 is involved in appearance of malignant phenotype of a lung adenocarcinoma cell (A549 cell). In line with our previous study, here we investigated if Src signaling could be involved in PGE2-stimulated growth of A549 cells via EP3. PGE2-dependent cell growth in A549 cell positively related to the activation of Src. A specific antagonist against EP3 abrogated the cell growth and Src activation in the cells stimulated with PGE2. Also, the inhibition of Src activity suppressed its downstream signaling related to cell growth as well as the cell growth in the cells treated with PGE2. These results indicate that PGE2-dependent activation of Src signaling via EP3 plays an important role in growth of A549 cells.

Found

Top-30

Journals

	1
Oncotarget	Oncotarget, 1, 2.78% Oncotarget 1 publication, 2.78%
Oncology Letters	Oncology Letters, 1, 2.78% Oncology Letters 1 publication, 2.78%
International Journal of Oncology	International Journal of Oncology, 1, 2.78% International Journal of Oncology 1 publication, 2.78%
Cancers	Cancers, 1, 2.78% Cancers 1 publication, 2.78%
Toxins	Toxins, 1, 2.78% Toxins 1 publication, 2.78%
Cell Biology and Toxicology	Cell Biology and Toxicology, 1, 2.78% Cell Biology and Toxicology 1 publication, 2.78%
Journal of Biomedical Science	Journal of Biomedical Science, 1, 2.78% Journal of Biomedical Science 1 publication, 2.78%
BMC Endocrine Disorders	BMC Endocrine Disorders, 1, 2.78% BMC Endocrine Disorders 1 publication, 2.78%
Cell Death and Disease	Cell Death and Disease, 1, 2.78% Cell Death and Disease 1 publication, 2.78%
Journal of Cancer Research and Clinical Oncology	Journal of Cancer Research and Clinical Oncology, 1, 2.78% Journal of Cancer Research and Clinical Oncology 1 publication, 2.78%
BMC Bioinformatics	BMC Bioinformatics, 1, 2.78% BMC Bioinformatics 1 publication, 2.78%
PLoS Pathogens	PLoS Pathogens, 1, 2.78% PLoS Pathogens 1 publication, 2.78%
Medical Hypotheses	Medical Hypotheses, 1, 2.78% Medical Hypotheses 1 publication, 2.78%
Biochemical and Biophysical Research Communications	Biochemical and Biophysical Research Communications, 1, 2.78% Biochemical and Biophysical Research Communications 1 publication, 2.78%
Annals of Oncology	Annals of Oncology, 1, 2.78% Annals of Oncology 1 publication, 2.78%
Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids	Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids, 1, 2.78% Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids 1 publication, 2.78%
Placenta	Placenta, 1, 2.78% Placenta 1 publication, 2.78%
Brain, Behavior, and Immunity	Brain, Behavior, and Immunity, 1, 2.78% Brain, Behavior, and Immunity 1 publication, 2.78%
European Journal of Pharmacology	European Journal of Pharmacology, 1, 2.78% European Journal of Pharmacology 1 publication, 2.78%
Translational Research	Translational Research, 1, 2.78% Translational Research 1 publication, 2.78%
Prostaglandins and Other Lipid Mediators	Prostaglandins and Other Lipid Mediators, 1, 2.78% Prostaglandins and Other Lipid Mediators 1 publication, 2.78%
FEBS Letters	FEBS Letters, 1, 2.78% FEBS Letters 1 publication, 2.78%
ChemMedChem	ChemMedChem, 1, 2.78% ChemMedChem 1 publication, 2.78%
International Journal of Cancer	International Journal of Cancer, 1, 2.78% International Journal of Cancer 1 publication, 2.78%
OncoTargets and Therapy	OncoTargets and Therapy, 1, 2.78% OncoTargets and Therapy 1 publication, 2.78%
Metallomics	Metallomics, 1, 2.78% Metallomics 1 publication, 2.78%
Toxicological Sciences	Toxicological Sciences, 1, 2.78% Toxicological Sciences 1 publication, 2.78%
Journal of Virology	Journal of Virology, 1, 2.78% Journal of Virology 1 publication, 2.78%
International Journal of Cell Biology	International Journal of Cell Biology, 1, 2.78% International Journal of Cell Biology 1 publication, 2.78%
Clinical Cancer Research	Clinical Cancer Research, 1, 2.78% Clinical Cancer Research 1 publication, 2.78%
	1

Publishers

	2 4 6 8 10
Elsevier	Elsevier, 10, 27.78% Elsevier 10 publications, 27.78%
Springer Nature	Springer Nature, 6, 16.67% Springer Nature 6 publications, 16.67%
Wiley	Wiley, 3, 8.33% Wiley 3 publications, 8.33%
Spandidos Publications	Spandidos Publications, 2, 5.56% Spandidos Publications 2 publications, 5.56%
MDPI	MDPI, 2, 5.56% MDPI 2 publications, 5.56%
Impact Journals	Impact Journals, 1, 2.78% Impact Journals 1 publication, 2.78%
Public Library of Science (PLoS)	Public Library of Science (PLoS), 1, 2.78% Public Library of Science (PLoS) 1 publication, 2.78%
Taylor & Francis	Taylor & Francis, 1, 2.78% Taylor & Francis 1 publication, 2.78%
Royal Society of Chemistry (RSC)	Royal Society of Chemistry (RSC), 1, 2.78% Royal Society of Chemistry (RSC) 1 publication, 2.78%
Oxford University Press	Oxford University Press, 1, 2.78% Oxford University Press 1 publication, 2.78%
American Society for Microbiology	American Society for Microbiology, 1, 2.78% American Society for Microbiology 1 publication, 2.78%
Hindawi Limited	Hindawi Limited, 1, 2.78% Hindawi Limited 1 publication, 2.78%
American Association for Cancer Research (AACR)	American Association for Cancer Research (AACR), 1, 2.78% American Association for Cancer Research (AACR) 1 publication, 2.78%
American Society of Hematology	American Society of Hematology, 1, 2.78% American Society of Hematology 1 publication, 2.78%
American Society of Clinical Oncology (ASCO)	American Society of Clinical Oncology (ASCO), 1, 2.78% American Society of Clinical Oncology (ASCO) 1 publication, 2.78%
American Physiological Society	American Physiological Society, 1, 2.78% American Physiological Society 1 publication, 2.78%
American Society for Pharmacology and Experimental Therapeutics	American Society for Pharmacology and Experimental Therapeutics, 1, 2.78% American Society for Pharmacology and Experimental Therapeutics 1 publication, 2.78%
	2 4 6 8 10

We do not take into account publications without a DOI.
Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.

Metrics

Cite this

GOST |

Cite this

GOST Copy

Yamaki T. et al. Prostaglandin E2 activates Src signaling in lung adenocarcinoma cell via EP3 // Cancer Letters. 2004. Vol. 214. No. 1. pp. 115-120.

GOST all authors (up to 50) Copy

Yamaki T., Endoh K., Miyahara M., Nagamine I., Huong N. T., Sakurai H., Pokorny J., Yano T. Prostaglandin E2 activates Src signaling in lung adenocarcinoma cell via EP3 // Cancer Letters. 2004. Vol. 214. No. 1. pp. 115-120.

RIS |

Cite this

RIS Copy

TY - JOUR

DO - 10.1016/j.canlet.2004.04.013

UR - https://doi.org/10.1016/j.canlet.2004.04.013

TI - Prostaglandin E2 activates Src signaling in lung adenocarcinoma cell via EP3

T2 - Cancer Letters

AU - Yamaki, Tatsuya

AU - Endoh, Kiyoko

AU - Miyahara, Mituyoshi

AU - Nagamine, Isao

AU - Huong, Nguyen Thanh

AU - Sakurai, Hidetoshi

AU - Pokorny, Jan

AU - Yano, Tomohiro

PY - 2004

DA - 2004/10/01

PB - Elsevier

SP - 115-120

IS - 1

VL - 214

PMID - 15331179

SN - 0304-3835

SN - 1872-7980

ER -

BibTex |

Cite this

BibTex (up to 50 authors) Copy

@article{2004_Yamaki,

author = {Tatsuya Yamaki and Kiyoko Endoh and Mituyoshi Miyahara and Isao Nagamine and Nguyen Thanh Huong and Hidetoshi Sakurai and Jan Pokorny and Tomohiro Yano},

title = {Prostaglandin E2 activates Src signaling in lung adenocarcinoma cell via EP3},

journal = {Cancer Letters},

year = {2004},

volume = {214},

publisher = {Elsevier},

month = {oct},

url = {https://doi.org/10.1016/j.canlet.2004.04.013},

number = {1},

pages = {115--120},

doi = {10.1016/j.canlet.2004.04.013}

}

MLA

Cite this

MLA Copy

Yamaki, Tatsuya, et al. “Prostaglandin E2 activates Src signaling in lung adenocarcinoma cell via EP3.” Cancer Letters, vol. 214, no. 1, Oct. 2004, pp. 115-120. https://doi.org/10.1016/j.canlet.2004.04.013.

Publisher

Elsevier

Journal

Cancer Letters

scimago Q1

wos Q1

SJR

2.756

CiteScore

13.9

Impact factor

10.1

ISSN

03043835 (Print)

18727980 (Electronic)